Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety

Exemestane (Exe) in combination with Everolimus (Eve) represents an important treatment option for patients diagnosed with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC), which was previously treated with non-steroidal aromat...

Full description

Saved in:
Bibliographic Details
Published in:Mol Clin Oncol
Main Authors: Riccardi, Ferdinando, Colantuoni, Giuseppe, Diana, Anna, Mocerino, Carmela, Cartenì, Giacomo, Lauria, Rossella, Febbraro, Antonio, Nuzzo, Francesco, Addeo, Raffaele, Marano, Ombretta, Incoronato, Pasquale, De Placido, Sabino, Ciardiello, Fortunato, Orditura, Michele
Format: Artigo
Language:Inglês
Published: D.A. Spandidos 2018
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6109668/
https://ncbi.nlm.nih.gov/pubmed/30155246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1672
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items